Guiyang Xintian Pharmaceutical (002873.SZ): Huilun Pharmaceutical has obtained the registration certificate for the pharmaceutical product of Empagliflozin and Metformin Extended-Release Tablets.
Gelonghui reported on March 3 that Guiyang Xintian Pharmaceutical (002873.SZ) announced that its associate company Shanghai Huilun Pharmaceutical Co., Ltd. (referred to as "Huilun Pharmaceutical") recently received the Drug Registration Certificate (certificate number: 2025S00532) approved and issued by the National Medical Products Administration for the empagliflozin and metformin extended-release tablets. The empagliflozin and metformin extended-release tablets are a compound formulation of empagliflozin and metformin, mainly used to lower blood sugar and effectively control type Ⅱ diabetes. The product combines the advantages of empagliflozin and metformin through different blood sugar-lowering mechanisms.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Xintian Pharma's Unit Secures Drug Business License
Guiyang Xintian Pharmaceutical (002873.SZ): has received 5 trademark registration certificates.
On January 13, Gelonghui reported that Guiyang Xintian Pharmaceutical (002873.SZ) announced that recently, Guiyang Xintian Pharmaceutical Co., Ltd. received five newly issued trademark registration certificates from the National Intellectual Property Administration.
Guiyang Xintian Pharmaceutical (002873.SZ) 2024 interim profit distribution plan: proposed to distribute 0.4 yuan per share.
Gelonghui December 2nd | Guiyang Xintian Pharmaceutical (002873.SZ) announced that, based on its actual operation and fully considering the maintenance of shareholders' interests, the company plans to distribute mid-term profits in 2024 as follows: using the total share capital on the registration date of the future profit distribution plan (excluding shares in the company's repurchase account) as the base, distributing a cash dividend of 0.40 yuan per 10 shares to all shareholders (including tax), no bonus shares, and no capital reserve conversion.
Xintian Pharmaceutical Amends Business License
Market Might Still Lack Some Conviction On Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) Even After 45% Share Price Boost
